SA521430813B1 - لقاح وحدات فرعية لعلاج عدوى الجهاز التنفسي أو الوقاية منها - Google Patents
لقاح وحدات فرعية لعلاج عدوى الجهاز التنفسي أو الوقاية منهاInfo
- Publication number
- SA521430813B1 SA521430813B1 SA521430813A SA521430813A SA521430813B1 SA 521430813 B1 SA521430813 B1 SA 521430813B1 SA 521430813 A SA521430813 A SA 521430813A SA 521430813 A SA521430813 A SA 521430813A SA 521430813 B1 SA521430813 B1 SA 521430813B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- respiratory tract
- prevention
- treatment
- tract infection
- subunit vaccine
- Prior art date
Links
- 206010057190 Respiratory tract infections Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 229940031626 subunit vaccine Drugs 0.000 title 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract 1
- 241000351643 Metapneumovirus Species 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175413 | 2019-05-20 | ||
| PCT/EP2020/063973 WO2020234300A1 (en) | 2019-05-20 | 2020-05-19 | A subunit vaccine for treatment or prevention of a respiratory tract infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA521430813B1 true SA521430813B1 (ar) | 2024-04-27 |
Family
ID=66685352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA521430813A SA521430813B1 (ar) | 2019-05-20 | 2021-11-10 | لقاح وحدات فرعية لعلاج عدوى الجهاز التنفسي أو الوقاية منها |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US12162907B2 (enExample) |
| EP (1) | EP3972639A1 (enExample) |
| JP (1) | JP2022533318A (enExample) |
| KR (1) | KR20220010478A (enExample) |
| CN (1) | CN114127101A (enExample) |
| AU (1) | AU2020277661A1 (enExample) |
| BR (1) | BR112021021637A2 (enExample) |
| CA (1) | CA3138064A1 (enExample) |
| CL (1) | CL2021002819A1 (enExample) |
| CO (1) | CO2021014694A2 (enExample) |
| EC (1) | ECSP21079178A (enExample) |
| GB (1) | GB2598494B (enExample) |
| IL (1) | IL287099A (enExample) |
| MX (1) | MX2021013111A (enExample) |
| MY (1) | MY208001A (enExample) |
| PE (1) | PE20220400A1 (enExample) |
| PH (1) | PH12021552736A1 (enExample) |
| SA (1) | SA521430813B1 (enExample) |
| SG (1) | SG11202110646PA (enExample) |
| WO (1) | WO2020234300A1 (enExample) |
| ZA (1) | ZA202106883B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8986704B2 (en) | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| WO2018189372A1 (en) | 2017-04-13 | 2018-10-18 | Valneva Austria Gmbh | Multivalent ospa polypeptides and methods and uses relating thereto |
| KR20220010478A (ko) | 2019-05-20 | 2022-01-25 | 발네바 에스이 | 기도 감염의 치료 또는 예방용 서브유닛 백신 |
| IL297166A (en) | 2020-04-09 | 2022-12-01 | Valneva Austria Gmbh | Compositions comprising three ospa fusion proteins for medical use |
| US20240026412A1 (en) | 2020-04-09 | 2024-01-25 | Valneva Austria Gmbh | Improved methods of producing a lipidated protein |
| IL320367A (en) | 2020-10-09 | 2025-06-01 | Univ Texas | Prefusion-stabilized hmpv f proteins |
| KR20230107621A (ko) | 2020-11-13 | 2023-07-17 | 아이코사백스, 인크. | 메타뉴모바이러스에 대한 단백질-기반 나노입자 백신 |
| KR20230167017A (ko) * | 2021-04-09 | 2023-12-07 | 발네바 에스이 | 인간 메타뉴모 바이러스 백신 |
| US20240335523A1 (en) * | 2021-08-05 | 2024-10-10 | The Regents Of The University Of California | Glycoengineered Foldon Domains and Related Compositions and Methods |
| EP4448802A1 (en) * | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| CN120548194A (zh) | 2023-01-18 | 2025-08-26 | 辉瑞公司 | 针对呼吸道疾病的疫苗 |
| CN121263205A (zh) * | 2023-02-06 | 2026-01-02 | 塞维卡有限责任公司 | 修饰的piv5疫苗载体：制造方法和用途 |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025201243A1 (zh) * | 2024-03-25 | 2025-10-02 | 中国医学科学院医学生物学研究所 | 重组呼吸道合胞病毒融合前f蛋白突变体和其用途 |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| CN119176858B (zh) * | 2024-11-22 | 2026-01-09 | 北京华诺泰生物医药科技有限公司 | 一种重组人偏肺病毒融合前f蛋白纯化方法 |
| CN122011136A (zh) * | 2026-04-13 | 2026-05-12 | 北京民海生物科技有限公司 | 一种融合前人偏肺病毒f蛋白的突变体及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5547871A (en) | 1993-01-25 | 1996-08-20 | American Cyanamid Company | Heterologous signal sequences for secretion of insect controlling proteins |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| AT408721B (de) | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
| AT409085B (de) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
| AT410173B (de) | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
| HU228264B1 (en) | 2000-06-08 | 2013-02-28 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| AU2001289813B2 (en) | 2000-08-17 | 2005-07-28 | Intercell Ag | A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof |
| AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| US8715922B2 (en) * | 2001-01-19 | 2014-05-06 | ViroNovative | Virus causing respiratory tract illness in susceptible mammals |
| EP1390494A2 (en) | 2001-05-21 | 2004-02-25 | Intercell AG | Method for stabilising of nucleic acids |
| US20050250716A1 (en) | 2001-12-07 | 2005-11-10 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| DE10221836A1 (de) * | 2002-05-16 | 2003-12-04 | Lohmann Animal Health Gmbh | Attenuierung von Metapneumovirus |
| AU2004224746B2 (en) | 2003-03-24 | 2009-04-23 | Valneva Austria Gmbh | Improved vaccines |
| CN101410519B (zh) * | 2003-04-25 | 2013-04-24 | 免疫医疗有限责任公司 | 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法 |
| SG176807A1 (en) | 2009-06-24 | 2012-01-30 | Id Biomedical Corp Quebec | Vaccine |
| WO2011050168A2 (en) | 2009-10-21 | 2011-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Rsv immunogens, antibodies and compositions thereof |
| CN102145167A (zh) * | 2010-02-05 | 2011-08-10 | 重庆医科大学附属儿童医院 | 重组人类偏肺病毒疫苗 |
| CN107029223A (zh) | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
| EP4400115A3 (en) | 2011-12-06 | 2024-10-23 | Valneva Austria GmbH | Aluminium compounds for use in therapeutics and vaccines |
| CN105408348B (zh) * | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| CL2013002829A1 (es) | 2013-10-01 | 2014-04-04 | Univ Pontificia Catolica Chile | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. |
| US10420834B2 (en) * | 2014-12-24 | 2019-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant metapneumovirus F proteins and their use |
| CN108348593B (zh) * | 2015-08-31 | 2022-08-16 | 泰克诺瓦克斯股份有限公司 | 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗 |
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| EP3474893A1 (en) | 2016-06-27 | 2019-05-01 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens |
| WO2019092002A1 (en) | 2017-11-07 | 2019-05-16 | Valneva Se | Pharmaceutical compositions for treatment or prevention of viral infections |
| KR20220010478A (ko) | 2019-05-20 | 2022-01-25 | 발네바 에스이 | 기도 감염의 치료 또는 예방용 서브유닛 백신 |
| KR20230167017A (ko) | 2021-04-09 | 2023-12-07 | 발네바 에스이 | 인간 메타뉴모 바이러스 백신 |
-
2020
- 2020-05-19 KR KR1020217034461A patent/KR20220010478A/ko not_active Ceased
- 2020-05-19 PE PE2021001766A patent/PE20220400A1/es unknown
- 2020-05-19 GB GB2114836.6A patent/GB2598494B/en active Active
- 2020-05-19 MY MYPI2021005570A patent/MY208001A/en unknown
- 2020-05-19 PH PH1/2021/552736A patent/PH12021552736A1/en unknown
- 2020-05-19 SG SG11202110646PA patent/SG11202110646PA/en unknown
- 2020-05-19 BR BR112021021637A patent/BR112021021637A2/pt unknown
- 2020-05-19 JP JP2021564088A patent/JP2022533318A/ja active Pending
- 2020-05-19 EP EP20726137.1A patent/EP3972639A1/en active Pending
- 2020-05-19 US US17/606,811 patent/US12162907B2/en active Active
- 2020-05-19 AU AU2020277661A patent/AU2020277661A1/en active Pending
- 2020-05-19 CA CA3138064A patent/CA3138064A1/en active Pending
- 2020-05-19 WO PCT/EP2020/063973 patent/WO2020234300A1/en not_active Ceased
- 2020-05-19 CN CN202080030901.9A patent/CN114127101A/zh active Pending
- 2020-05-19 MX MX2021013111A patent/MX2021013111A/es unknown
-
2021
- 2021-09-17 ZA ZA2021/06883A patent/ZA202106883B/en unknown
- 2021-10-07 IL IL287099A patent/IL287099A/en unknown
- 2021-10-25 EC ECSENADI202179178A patent/ECSP21079178A/es unknown
- 2021-10-26 CL CL2021002819A patent/CL2021002819A1/es unknown
- 2021-10-29 CO CONC2021/0014694A patent/CO2021014694A2/es unknown
- 2021-11-10 SA SA521430813A patent/SA521430813B1/ar unknown
-
2023
- 2023-10-24 US US18/493,004 patent/US12162909B2/en active Active
-
2024
- 2024-10-31 US US18/932,700 patent/US20250171501A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220010478A (ko) | 2022-01-25 |
| CO2021014694A2 (es) | 2022-01-17 |
| US20240067681A1 (en) | 2024-02-29 |
| GB202114836D0 (en) | 2021-12-01 |
| GB2598494A (en) | 2022-03-02 |
| BR112021021637A2 (pt) | 2021-12-21 |
| EP3972639A1 (en) | 2022-03-30 |
| US20220185847A1 (en) | 2022-06-16 |
| GB2598494B (en) | 2024-07-24 |
| WO2020234300A1 (en) | 2020-11-26 |
| PE20220400A1 (es) | 2022-03-22 |
| IL287099A (en) | 2021-12-01 |
| MY208001A (en) | 2025-04-03 |
| AU2020277661A1 (en) | 2021-10-21 |
| CA3138064A1 (en) | 2020-11-26 |
| MX2021013111A (es) | 2021-11-17 |
| CL2021002819A1 (es) | 2022-07-08 |
| ZA202106883B (en) | 2022-07-27 |
| JP2022533318A (ja) | 2022-07-22 |
| ECSP21079178A (es) | 2021-11-30 |
| US12162909B2 (en) | 2024-12-10 |
| US12162907B2 (en) | 2024-12-10 |
| CN114127101A (zh) | 2022-03-01 |
| PH12021552736A1 (en) | 2022-07-11 |
| SG11202110646PA (en) | 2021-10-28 |
| US20250171501A1 (en) | 2025-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY208001A (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
| CR20210306A (es) | Proteínas f de prefusión del vrs estabilizadas | |
| MX2020010941A (es) | Moleculas y composiciones novedosas de arn de vsr para vacunacion. | |
| EA201070794A1 (ru) | Рекомбинантные антигены rsv | |
| MX2023010370A (es) | Vacuna del metapneumovirus humano. | |
| JOP20220349A1 (ar) | توليفة لقاح ضد الإصابة بفيروس مخلوي تنفسي | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| CY1117673T1 (el) | Ανασυνδυασμενα αντιγονα rsv | |
| PH12018502332A1 (en) | Stabilized pre-fusion rsv f proteins | |
| MX395525B (es) | Composiciones inmunogenicas para usar en vacunas neumococicas. | |
| PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
| MX2011006205A (es) | Proteinas f del vrs modificadas y metodos de uso de las mismas. | |
| WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
| PH12013501373B1 (en) | Bovine viral diarrhea virus type 1b vaccine compositions and methods | |
| MX2021013947A (es) | Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus. | |
| MX2020008454A (es) | Composicion inmunogenica que comprende antigenos estafilococicos. | |
| MX2023009447A (es) | Anticuerpos que se unen a metapneumovirus, proteínas antigénicas de metapneumovirus, y usos de los mismos. | |
| MY170991A (en) | Dosing regimens of celgosivir for the treatment of dengue | |
| SA520411067B1 (ar) | تركيبات صلبة فموية من بيتا هستين ممتدة الإطلاق غير نابضة | |
| MX2021001228A (es) | Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria. | |
| ATE454896T1 (de) | Heilkräuterzusammensetzung zur behandlung von aids | |
| MX2023005221A (es) | Composiciones inmunogenicas para uso en vacunas neumococicas. | |
| MX2022008036A (es) | Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv. | |
| MX2021015494A (es) | Profarmacos de quinazolina para el tratamiento de infecciones viricas y otras enfermedades. | |
| EA202191384A1 (ru) | 3,3-дифтораллиламины или их соли и содержащие их фармацевтические композиции |